|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Adoptive immunotherapy for acute leukemia:New insights in chimeric antigen receptors显示文摘Relapses remain a major concern in acute leukemia. It is well known that leukemia stem cells(LSCs) hide in hematopoietic niches and escape to the immune system surveillance through the outgrowth of poorly immunogenic tumor-cell variants and the suppression of the active immune response. Despitethe introduction of new reagents and new therapeutic approaches, no treatment strategies have been able to definitively eradicate LSCs. However, recent adoptive immunotherapy in cancer is expected to revolutionize our way to fight against this disease, by redirecting the immune system in order to eliminate relapse issues. Initially described at the onset of the 90's, chimeric antigen receptors(CARs) are recombinant receptors transferred in various T cell subsets, providing specific antigens binding in a non-major histocompatibility complex restricted manner, and effective on a large variety of human leukocyte antigen-divers cell populations. Once transferred, engineered T cells act like an expanding 'living drug' specifically targeting the tumor-associated antigen, and ensure long-term antitumor memory. Over the last decades, substantial improvements have been made in CARs design. CAR T cells have finally reached the clinical practice and first clinical trials have shown promising results. In acute lymphoblastic leukemia, high rate of complete and prolonged clinical responses have been observed after anti-CD19 CAR T cell therapy, with specific but manageable adverse events. In this review, our goal was to describe CAR structures and functions, and to summarize recent data regarding pre-clinical studies and clinical trials in acute leukemia. | Mael Heiblig Mohamed Elhamri Mauricette Michallet Xavier Thomas | 2015 | World Journal of Stem Cells2015，7，7： | 9 |
| 2 | Mobilization of CD34^+CD38^- hematopoietic stem cells after priming in acute myeloid leukemia显示文摘AIM: To evaluate quantitatively and qualitatively the different CD34+cell subsets after priming by chemotherapy granulocyte colony-stimulating factor(± G-CSF)in patients with acute myeloid leukemia.METHODS: Peripheral blood and bone marrow sampleswere harvested in 8 acute myeloid leukemia patients during and after induction chemotherapy. The CD34/CD38 cell profile was analyzed by multi-parameter flow cytometry. Adhesion profile was made using CXC chemokine receptor 4(CXCR4)(CD184), VLA-4(CD49d/CD29) and CD47.RESULTS: Chemotherapy ± G-CSF mobilized immature cells(CD34+CD38 population), while the more mature cells(CD34+CD38lowand CD34+CD38+populations) decreased progressively after treatment. Circulating CD34+cells tended to be more sensitive to chemotherapy after priming with G-CSF. CD34+cell mobilization was correlated with a gradual increase in CXCR4 and CD47expression, suggesting a role in cell protection and the capacity of homing back to the marrow.CONCLUSION: Chemotherapy ± G-CSF mobilizes into the circulation CD34+bone marrow cells, of which, the immature CD34+CD38-cell population. Further manipulations of these interactions may be a means with which to control the trafficking of leukemia stem cells to improve patients' outcomes. | Adriana Plesa Eve Mattei Charles Dumontet Youcef Chelghoum Hélène Labussière Giovanna Cannas Mauricette Michallet Xavier Thomas Mohamed Elhamri Stéphane Morisset Inès Tagoug | 2013 | World Journal of Stem Cells2013，5，4： | 1 |
| 3 | Clofarabine for the treatment of adult acute myeloid leukemia 显示文摘 | Thomas X Raffoux E Elhamri M | 2009 | Future Oncology2009，5，8： | 1 |
| 4 | Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial显示文摘 | THOMAS X ELHAMRI M CHELGHOUM Y | 2005 | Ann Hematol2005，84，： | 1 |
| 5 | High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia显示文摘AIM To evaluate the importance of the CD34+CD38-cell population when compared to the CD34+CD38+/low and CD34+CD38+/high leukemic cell sub-populations and to determine its correlations with leukemia characteristics and known prognostic factors, as well as with response to therapy and survival.METHODS Two hundred bone marrow samples were obtained at diagnosis from 200 consecutive patients with newly diagnosed acute myeloid leukemia(AML) were studied between September 2008 and December 2010 at our Institution(Hematology Department, Lyon, France). The CD34/CD38 cell profile was analyzed by multiparameter flowcytometry approach using 8 C panels and FACS CANTO and Diva software(BD Bioscience).RESULTS We analyzed CD34 and CD38 expression in bone marrow samples of 200 AML patients at diagnosis, and investigated the prognostic value of the most immature CD34+CD38-population. Using a cut-off value of 1% of CD34+CD38-from total 'bulk leukemic cells' we found that a high(> 1%) level of CD34+CD38-blasts at diagnosis was correlated with advanced age, adverse cytogenetics as well as with a lower rate of complete response after induction and shorter disease-free survival. In a multivariate analysis considering age, leukocytosis, the % of CD34+ blasts cells and the standardized cytogenetic and molecular risk subgroups, a percentage of CD34+CD38-leukemic cells > 1% was an independent predictor of DFS [HR = 2.8(1.02-7.73), P = 0.04] and OS [HR = 2.65(1.09-6.43), P = 0.03].CONCLUSION Taken together, these results show that a CD34/CD38 'backbone' for leukemic cell analysis by multicolour flowcytometry at diagnosis provides useful prognostic information. | Adriana Plesa Charles Dumontet Eve Mattei Ines Tagoug Sandrine Hayette Pierre Sujobert Isabelle Tigaud Marie Pierre Pages Youcef Chelghoum Fiorenza Baracco Helene Labussierre Sophie Ducastelle Etienne Paubelle Franck Emmanuel Nicolini Mohamed Elhamri Lydia Campos Claudiu Plesa Stéphane Morisset Gilles Salles Yves Bertrand Mauricette Michallet Xavier Thomas | 2017 | World Journal of Stem Cells2017，9，12： | 1 |
| 6 | Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors显示文摘 | Tavernier E Le QH Elhamri M | 2003 | Leuk Res2003，27，3： | 1 |
| 7 | Clofarabine for the treatment of adult acute myeloid leukemia显示文摘 | Thomas X Raffoux E Elhamri M | 2009 | Future Oncology2009，5，8： | 1 |
| 8 | Comparison of high-dose cytarabiue and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission:the ALFA-9802 study显示文摘 | Thomas X Elhamri M Raffoux E | | 0，，07： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员